全文获取类型
收费全文 | 1130469篇 |
免费 | 78758篇 |
国内免费 | 4744篇 |
专业分类
耳鼻咽喉 | 15507篇 |
儿科学 | 35387篇 |
妇产科学 | 29571篇 |
基础医学 | 159867篇 |
口腔科学 | 30564篇 |
临床医学 | 101697篇 |
内科学 | 212714篇 |
皮肤病学 | 25082篇 |
神经病学 | 84166篇 |
特种医学 | 45367篇 |
外国民族医学 | 235篇 |
外科学 | 169790篇 |
综合类 | 30646篇 |
现状与发展 | 16篇 |
一般理论 | 277篇 |
预防医学 | 78364篇 |
眼科学 | 25833篇 |
药学 | 92302篇 |
59篇 | |
中国医学 | 5851篇 |
肿瘤学 | 70676篇 |
出版年
2021年 | 10352篇 |
2019年 | 9581篇 |
2018年 | 13254篇 |
2017年 | 10659篇 |
2016年 | 11832篇 |
2015年 | 13666篇 |
2014年 | 18297篇 |
2013年 | 25249篇 |
2012年 | 34777篇 |
2011年 | 36785篇 |
2010年 | 21895篇 |
2009年 | 20233篇 |
2008年 | 33132篇 |
2007年 | 35299篇 |
2006年 | 35675篇 |
2005年 | 33807篇 |
2004年 | 31945篇 |
2003年 | 30621篇 |
2002年 | 29394篇 |
2001年 | 61442篇 |
2000年 | 62837篇 |
1999年 | 52194篇 |
1998年 | 13177篇 |
1997年 | 11737篇 |
1996年 | 11613篇 |
1995年 | 10824篇 |
1994年 | 9795篇 |
1993年 | 9155篇 |
1992年 | 38214篇 |
1991年 | 36602篇 |
1990年 | 36044篇 |
1989年 | 34543篇 |
1988年 | 31091篇 |
1987年 | 30193篇 |
1986年 | 28372篇 |
1985年 | 26577篇 |
1984年 | 19279篇 |
1983年 | 16181篇 |
1982年 | 8870篇 |
1979年 | 17083篇 |
1978年 | 11430篇 |
1977年 | 10246篇 |
1976年 | 8858篇 |
1975年 | 10088篇 |
1974年 | 11682篇 |
1973年 | 11299篇 |
1972年 | 10782篇 |
1971年 | 10118篇 |
1970年 | 9275篇 |
1969年 | 8955篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
11.
Jesus K Yamamoto-Furusho Norma N Parra-Holgu n 《World journal of gastroenterology : WJG》2021,27(48):8242-8261
Inflammatory bowel disease (IBD) is a chronic disease that requires chronic treatment throughout the evolution of the disease, with a complex physiopathology that entails great challenges for the development of new and specific treatments for ulcerative colitis and Crohn´s disease. The anti-tumor necrosis factor alpha therapy has impacted the clinical course of IBD in those patients who do not respond to conventional treatment, so there is a need to develop new therapies and markers of treatment response. Various pathways involved in the development of the disease are known and the new therapies have focused on blocking the inflammatory process at the gastrointestinal level by oral, intravenous, subcutaneous, and topical route. All these new therapies can lead to more personalized treatments with higher success rates and fewer relapses. These treatments have not only focused on clinical remission, but also on achieving macroscopic changes at the endoscopic level and microscopic changes by achieving mucosal healing. These treatments are mainly based on modifying signaling pathways, by blocking receptors or ligands, reducing cell migration and maintaining the integrity of the epithelial barrier. Therefore, this review presents the efficacy and safety of the new treatments that are currently under study and the advances that have been made in this area in recent years. 相似文献
12.
13.
Comprehensive evidence regarding the treatment of non-anaemic iron deficiency in patients undergoing valvular heart surgery is lacking. This study aimed to investigate the association between non-anaemic iron deficiency and postoperative outcomes in these patients. We retrospectively analysed 321 patients of which 180 (56%) had iron deficiency (defined as serum ferritin < 100 ng.ml-1 or < 300 ng.ml-1 with transferrin saturation < 20%). While the iron-deficient group had lower pre-operative haemoglobin levels than the non-iron deficient group (median (IQR [range]) 134 (127–141 [120–172]) g.l-1, 143 (133–150 [120–179]) g.l-1, p = 0.001), there was no between-group difference in allogeneic red blood cell transfusion. Median (IQR [range]) days alive and out of hospital at postoperative day 90 was 1 day shorter in the iron-deficient group (80 (77–82 [9–85]) days vs. 81 (79–83 [0–85]) days, p = 0.026). In multivariable analysis, only cardiopulmonary bypass duration (p = 0.032) and intra-operative allogeneic red blood cell transfusion (p = 0.011) were significantly associated with reduced days alive and out of hospital at postoperative day 90. Iron deficiency did not exert any adverse influence on secondary outcomes except length of hospital stay. Our findings indicate that non-anaemic iron deficiency alone is not associated with adverse effects in patients undergoing valvular heart surgery when it does not translate into an increased risk of allogeneic transfusion. 相似文献
14.
15.
Weina Cheng Yazhi Wang Jingxian Liu Xiaofei Li Ming Yu Cancan Duan Liu Liu Jianyong Zhang 《Journal of applied toxicology : JAT》2022,42(6):970-980
Cantharidin (CTD) is an effective antitumor agent. However, it exhibits significant hepatotoxicity, the mechanism of which remains unclear. In this study, biochemical and histopathological analyses complemented with ultra-high-performance liquid chromatography–tandem mass spectrometry (UHPLC-MS/MS)-based targeted metabolomic analysis of bile acids (BAs) were employed to investigate CTD-induced hepatotoxicity in rats. Sixteen male and female Sprague–Dawley rats were randomly divided into two groups: control and CTD (1.0 mg/kg) groups. Serum and liver samples were collected after 28 days of intervention. Biochemical, histopathological, and BA metabolomic analyses were performed for all samples. Further, the key biomarkers of CTD-induced hepatotoxicity were identified via multivariate and metabolic pathway analyses. In addition, metabolite–gene–enzyme network and Kyoto Encyclopedia of Genes and Genomes pathway analyses were used to identify the signaling pathways related to CTD-induced hepatotoxicity. The results revealed significantly increased levels of biochemical indices (alanine aminotransferase, aspartate aminotransferase, and total bile acid). Histopathological analysis revealed that the hepatocytes were damaged. Further, 20 endogenous BAs were quantitated via UHPLC-MS/MS, and multivariate and metabolic pathway analyses of BAs revealed that hyocholic acid, cholic acid, and chenodeoxycholic acid were the key biomarkers of CTD-induced hepatotoxicity. Meanwhile, primary and secondary BA biosynthesis and taurine and hypotaurine metabolism were found to be associated with the mechanism by which CTD induced hepatotoxicity in rats. This study provides useful insights for research on the mechanism of CTD-induced hepatotoxicity. 相似文献
16.
Malunguja Gisandu K. Devi Ashalata 《Proceedings of the National Academy of Sciences, India. Section B.》2022,92(1):105-120
Proceedings of the National Academy of Sciences, India Section B: Biological Sciences - Heavy metal concentrations in surface soils of Reserved Forests (RFs) have a significant impact on... 相似文献
17.
Purnima Gogoi Geetika Kaur Nikhlesh K Singh 《World journal of gastroenterology : WJG》2022,28(46):6497-6511
Colorectal cancer (CRC) is the third most diagnosed cancer and the second leading cause of cancer-related mortality in the United States. Across the globe, people in the age group older than 50 are at a higher risk of CRC. Genetic and environmental risk factors play a significant role in the development of CRC. If detected early, CRC is preventable and treatable. Currently, available screening methods and therapies for CRC treatment reduce the incidence rate among the population, but the micrometastasis of cancer may lead to recurrence. Therefore, the challenge is to develop an alternative therapy to overcome this complication. Nanotechnology plays a vital role in cancer treatment and offers targeted chemotherapies directly and selectively to cancer cells, with enhanced therapeutic efficacy. Additionally, nanotechnology elevates the chances of patient survival in comparison to traditional chemotherapies. The potential of nanoparticles includes that they may be used simultaneously for diagnosis and treatment. These exciting properties of nanoparticles have enticed researchers worldwide to unveil their use in early CRC detection and as effective treatment. This review discusses contemporary methods of CRC screening and therapies for CRC treatment, while the primary focus is on the theranostic approach of nanotechnology in CRC treatment and its prospects. In addition, this review aims to provide knowledge on the advancement of nanotechnology in CRC and as a starting point for researchers to think about new therapeutic approaches using nanotechnology. 相似文献
18.
19.
20.